STUDresearch · Peptide
CJC-1295 with DAC
Also known as
CJC-1295 DAC · CJC DAC · Drug Affinity Complex CJC · DAC:GRF · DAC-GRF · CJC-1295 (with DAC) · long-acting CJC-1295 · CJC1295 DAC · CJC-1295 · albumin-binding CJC-1295 · ConjuChem DAC:GRF
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Systemic
SubQ
Growth hormone axis
Systemic — long-acting GHRH analog with a DAC that binds albumin; multi-day GH stimulation and downstream IGF-1 elevation, not local tissue repair.
What people say
CJC-1295 with DAC is an albumin-binding, long-acting GHRH analog. It is a different active moiety and timing product from CJC-1295 without DAC/Mod GRF 1-29, despite inconsistent marketplace naming.
Doses people talk about
Rows report preserved amounts only. Multi-day exposure means a weekly total is not a simple conversion into short-acting CJC or an instruction.
How it may feel
Many accounts describe little acute effect; others mention flushing, warmth, fluid retention, puffy hands or joint stiffness. One inspected user said water retention and stiff hands emerged after a couple of weeks and led them to stop.
Common community weekly totalAbout 1–2 mg total per week
Modal research-chemical discussion for the DAC form; not a no-DAC amount.
Once-weekly chartAbout 2 mg as one weekly SubQ administration
Widely repeated protocol-chart amount, not established as a personal standard.
Twice-weekly split chartAbout 1 mg plus 1 mg, spaced roughly three to four days
A community exposure-smoothing pattern; the preference claim is not trial evidence.
Lower vendor-chart bandAbout 300–600 mcg per administration, once or twice weekly
A separate lower-amount camp, not a consensus maintenance range.
Single-dose clinical arms30, 60, 125 or 250 mcg/kg SubQ
Small healthy-adult study doses, not gym-chart amounts or evidence of long-term safety.
Half-life & effect duration
- Half-life in the body
- Single-dose studyAbout 5.8–8.1 days
- Repeated-dose estimatesAbout 5.4–9.2 days
- Felt duration people report
- Early reportsFirst-dose flushing or better sleep
- After a couple of weeksWater retention or stiff hands in some accounts
Cycles people discuss
Community discussion commonly uses 8–12-week blocks with variable breaks, while some people continue weekly use for months. These self-protocols are not the same as the small clinical dosing studies.
Timing
Small subcutaneous studies measured multi-day half-lives and hormone elevation lasting days after one dose. Those kinetics explain a slow offset, but they do not make community weekly schedules safe or turn edema resolution into a precise drug-clearance clock.
Around the dose
Clock: A few times per week, not a nightly ritual like no-DAC CJC.
Stacks
Discussion includes solo DAC, DAC plus Ipamorelin, and switching to rather than stacking with no-DAC CJC. These strategies create different exposure patterns and confounding.
Watch for
Harder to reverse quickly: Multi-day half-life means sides do not clear as fast as after a single no-DAC pulse — practical titration caution.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Small subcutaneous multiple-dose studies estimated a multi-day CJC-1295 half-life.
FDA's review reports mean half-life estimates of 5.4–9.2 days in samples collected through 14 days; single-dose DAC measurements were reported up to about eight days, with measurable drug 10–13 days later.
Very small healthy-adult studies; inconsistent naming and unspecified salt/form details. The estimate is for the DAC active moiety and cannot be transferred to no-DAC CJC.
- FDA Pharmacy Compounding Advisory Committee review memorandum — CJC-1295-related substances (opens in a new tab)PDF pp. 6–9 distinguish DAC and free-base active moieties; pp. 37–38 summarize subcutaneous Cmax, 5.4–9.2-day multiple-dose half-life, up-to-8-day DAC half-life and GH/IGF-1 persistence; pp. 50–52 discuss study-form limits.Regulatory review of small, incompletely reported studies; nomenclature and salt/form details are inconsistent, and repeated administration was not evaluated for approved therapeutic use.
Felt duration people report
The inspected accounts do not establish a repeatable per-dose felt-duration window for DAC.
Reports range from a first-dose flush or improved sleep to water retention and stiff hands emerging after a couple of weeks. One user had been off about two weeks when discussing the adverse course, but did not provide a resolved-at timestamp.
Unverified product and dose, sparse follow-up, accumulated endocrine exposure, and no blinded comparator; symptom onset or persistence is not the plasma half-life.
- CJC-1295 DAC half-life / side effects (opens in a new tab)Comment describing 1 mg once weekly, water retention and stiff hands after a couple of weeks, discontinuation, and being off for about two weeks; commenter said no other secretagogues were used.Single self-report with unverified product, no labs, no symptom-resolution timestamp and no medical attribution.
- CJC-1295 DAC — community experiences (opens in a new tab)Replies include distinct reports of water weight at 400 mcg twice weekly, no side effects and good sleep after two nights at 1 mg weekly, and facial flushing after a first 1 mg dose.Different authors, products and schedules; short follow-up, no same-author resolution and no objective endocrine or safety measurements.
What people say
- Convenience: Once-weekly or twice-weekly schedule vs multi-daily no-DAC + GHRP pins — main real-world adoption driver. forum
- Recovery talk: Easier next-day readiness / less soreness over multi-week runs — heavily confounded by sleep, training, and co-peptides. forum
- Recomp talk: Gradual lean-mass support and soft fat-loss assist over months, not week-one drama or a standalone fat burner. forum
- Sleep: Some report deeper sleep while IGF-1 is elevated; many feel little daytime difference after the first flush window. forum
- Fullness / skin: Mild GH-like fullness or skin-quality notes; early water retention can fake a “full” look. anecdote
- Vs no-DAC preference split: DAC fans prioritize compliance and steady IGF-1; pulse purists prefer Mod GRF + Ipamorelin for sharp peaks and natural-like troughs between shots. Neither physique superiority is settled by modern head-to-head RCTs. forum
- Vs exogenous GH: Framed as “stimulate your own GH” with pituitary feedback still in play — forum outcomes still generally described as milder than high-dose somatropin. forum
- Lab surrogate: Community and clinic-style users often track morning serum IGF-1 (and sometimes fasting glucose) after several weeks as an “axis engaged” check — not a proven bodycomp endpoint. forum
- GH rise (single dose, trial): Dose-dependent mean plasma GH increases ~2- to 10-fold lasting ≥~6 days after one subq injection. trial
- IGF-I rise (single dose, trial): Mean IGF-I ~1.5- to 3-fold for ~9–11 days after one dose. trial
- Multi-dose IGF-I: After repeated CJC-1295 doses, mean IGF-I remained above baseline up to ~28 days; cumulative effect noted. trial
- Tolerability band (trial): Authors concluded safe and relatively well tolerated particularly at 30 or 60 µg/kg subq; no serious adverse reactions reported in those healthy-adult PK studies. trial
Doses people talk about
- Common weekly band: ~1–2 mg total per week is the modal research-chem / forum figure for DAC. forum
- Once-weekly standard: ~2 mg (2,000 mcg) as a single subq shot once per week is widely repeated in protocol charts. forum
- Twice-weekly split: ~1 mg Monday + ~1 mg Thursday (or similar ~3–4 day spacing) for steadier exposure and smaller per-bolus volume — many prefer this over one big weekly bolus. forum
- Conservative / start: ~0.5–1 mg/week (or ~500–1,000 mcg once weekly, or ~500 mcg twice weekly) for lower IGF-1 targets, side sensitivity, or first exposure. forum
- Higher talk: Toward ~2–3 mg/week total appears in aggressive logs — more water/joint/glucose debate than proven incremental physique upside. forum
- Alternate low charts: Some vendor-style tables list ~300–600 mcg per injection once or twice weekly as a “maintenance” band — lower than the 1–2 mg culture; treat as a separate camp, not a consensus. forum
- Do not 1:1 swap with no-DAC: No-DAC / Mod GRF is typically ~100–300 mcg multi-daily; DAC is mg-scale weekly. Converting one into the other by arithmetic is a classic error. forum
- Empty-stomach strictness: Less ritualized than short-pulse stacks because exposure lasts days; some still prefer consistent weekday timing and avoid large carb boluses right at injection out of GH-axis habit. forum
- Uncertainty: Gray-market fill accuracy, DAC vs no-DAC mislabel, and underdosed vials are structural risks without third-party testing. forum
- Do not treat premixed CJC/Ipa daily blends as DAC math: Most commercial “CJC-1295 / Ipamorelin” pens and daily blends are no-DAC + Ipa microgram stacks — check the label for DAC vs no-DAC before using weekly milligram logic. forum
- Trial µg/kg context (not a gym chart): Teichman single-dose arms used 30, 60, 125, and 250 µg/kg subq; multi-dose used weekly or biweekly schedules. Authors highlighted better tolerability narrative at 30–60 µg/kg. For a ~80 kg adult, 30 µg/kg ≈ 2.4 mg and 60 µg/kg ≈ 4.8 mg per injection — clinical study scale, not community “start here.” trial
- Ionescu pulse study doses: 60 or 90 µg/kg single injection before overnight GH sampling — again PK/PD research scale. trial
- Framing: Community, research-chem, and clinic-marketing ranges only — not prescriptions, not medical advice, not safety-validated athletic protocols. forum
How it may feel
- Minutes–hours post-shot: Often nothing acute; subset reports facial/chest flush, warmth, or injection-site sting that fades. forum
- Days 1–3: Mostly site awareness; multi-day half-life means no “pulse crash” the next morning like short GHRH. forum
- Week 1: Minimal daytime feel for many; possible mild water retention, facial puffiness, or ring tightness as fluid shifts start. forum
- Weeks 2–4: Checkpoint for sleep quality, recovery feel, edema, joint stiffness, headache; physique change still subtle if present. forum
- Weeks 4–6: Common reassess window — if zero subjective or lab signal, community troubleshooting prioritizes real DAC content / purity over automatic dose-up. forum
- Weeks 6–8: Leaner look / fuller muscle anecdotes more common here when diet/training cooperate — still confounded. anecdote
- Months 2–3: Weigh fluid retention vs recovery wins; optional IGF-1 and metabolic labs; decide continue, split dose, lower mg/week, or switch to no-DAC pulse stack. forum
- After stop: Effects and residual IGF-1 elevation fade over days to 1–2+ weeks (multi-day half-life), not overnight — plan labs and “off” weeks accordingly. forum
Around the dose
- Clock: A few times per week, not a nightly ritual like no-DAC CJC. forum
- Sleep / food: Still GH-axis — people keep the pin away from a big carb meal. forum
- Training: Not pre-workout. Water/joint tightness is a reason some avoid pinning into a heavy squat day. forum
Cycles people discuss
- Common on-block: 8–12 weeks on is the most repeated community length for DAC runs. forum
- Extended: 12–16 weeks on appears in convenience / “set and forget” logs before a planned break. forum
- Time off: Often ~4 weeks off after 8–12+ weeks on; some use 4–8 weeks off or roughly equal on/off folklore. Practices vary. forum
- Clinic-style year plans: Multi-month weekly use with periodic labs (e.g. ~3 months on / ~1 month off style talk borrowed from broader CJC/Ipa wellness marketing). forum
- Continuous vs cycles: Some stay on weekly pins for many months for compliance; others cycle off over concerns about sustained trough GH elevation and desensitization lore. forum
- Short probe: 4–6 weeks to check sides (water, glucose feel, joints) and optional IGF-1 movement before committing multi-vial cost. forum
- Re-runs: Seasonal cut/bulk or heavy training restarts; long-term safety data in healthy athletes remain thin. forum
- No AAS-style PCT: Not treated like steroids; no universal SERM post-cycle protocol — just time off, sleep, training, and metabolic recheck if labs were used. forum
- Missed weekly dose: Community default is resume next scheduled day — do not double-stack two full weekly doses into one sitting without a reason. forum
- Desensitization debate: Pulse camps argue continuous DAC trough elevation is less “physiological” than multi-daily no-DAC; Ionescu data still showed preserved pulse frequency — debate is preference and theory more than settled outcome science. forum
Timing
- Vs no-DAC / Mod GRF: No-DAC ~30 min half-life → multi-daily pulses; DAC ~days → weekly schedule. Different products, different math. forum
- Vs native GHRH: Native GHRH half-life often cited on the order of minutes (~7 min talk in secondary summaries) — DAC’s point is escaping that. forum
- Washout planning: Residual elevation days after last shot — schedule “off week” labs and side resolution with multi-day lag in mind. forum
- Downstream cascade: Acute peptide peak hours-scale; GH elevation days-scale; bodycomp anecdotes weeks-to-months scale. forum
- Half-life (human, Teichman): Estimated ~5.8–8.1 days after subcutaneous dose in the single-dose study; multi-dose estimates sometimes cited ~5.4–9.2 days depending on sampling. trial
- Tmax: Maximum CJC-1295 concentrations typically within ~0.5–2 h (often ~1–1.5 h in single-dose groups). trial
- Measurable drug: Concentrations measurable ~10–14 days in multi-dose descriptions; slow exponential decline over several days. trial
- Why weekly / biweekly: Multi-day residence justifies once- or twice-weekly pins vs multi-daily short GHRH. Trial multi-dose arms used weekly or biweekly schedules. trial
- GH duration after one dose: Mean GH elevated ~2- to 10-fold for ≥~6 days. trial
- IGF-I duration after one dose: ~1.5- to 3-fold for ~9–11 days. trial
- Multi-dose accumulation: Mean IGF-I above baseline up to ~28 days; Cmax/AUC accumulation signals on later weekly doses in PK writeups. trial
- Pulse vs plateau (bro framing): Community “GH bleed” language = elevated baseline/trough for days; formal sampling still found episodic pulses preserved with higher troughs (Ionescu & Frohman). trial
More on what it is
- Why people use it: Convenience — one or two pins per week vs multi-daily no-DAC + GHRP stacks; steadies IGF-1 without daily compliance. forum
- Naming trap: “CJC-1295” without qualifier often means the DAC form in papers; research-chem culture also sells “CJC-1295 no DAC” (Mod GRF 1–29). They are not interchangeable PK products. forum
- What it is: Synthetic long-acting GHRH analog developed by ConjuChem (DAC:GRF). Core is tetra-substituted GRF 1–29 (same backbone idea as Mod GRF) plus a C-terminal Drug Affinity Complex (Nɛ-maleimidopropionyl-Lys) that covalently binds serum albumin after injection. trial
- Why DAC exists: Albumin bioconjugation extends half-life from ~minutes (native GHRH / short Mod GRF) to multi-day residence so weekly or twice-weekly subq dosing can sustain GH/IGF-1. trial
- Mechanism: Stimulates pituitary GHRH receptors → endogenous GH release → hepatic/peripheral IGF-1. Requires an intact pituitary; not exogenous rGH. trial
- Pulse nuance (Ionescu & Frohman 2006): Overnight sampling 1 week after 60 or 90 µg/kg showed GH pulse frequency and magnitude preserved, but basal (trough) GH rose ~7.5-fold and mean GH ~46% with IGF-I ~+45% — so “GH bleed” talk is really elevated trough + pulses riding on top, not complete loss of pulsatility. trial
- Key PK/PD trial: Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683) — single and multi-dose subq in healthy adults 21–61 yr; dose-dependent GH/IGF-I rises; half-life ~5.8–8.1 d; relatively well tolerated especially at 30–60 µg/kg. trial
- Development halt: Phase II lipodystrophy / visceral-obesity program (ConjuChem, ~2006; NCT00267527 discussed in secondary sources) was discontinued after a trial participant death; attending physician favored unrelated CAD/plaque rupture, but research stopped as precaution. trial
- Not: Not recombinant HGH, not a steroid/SARM, not Mod GRF / CJC no-DAC, not FDA-approved for muscle, fat loss, sleep, or anti-aging. trial
- IUPAC-style framing: Often written Nɛ30-maleimidopropionyl-[D-Ala2, Gln8, Ala15, Leu27]-Sermorelin-Lys30; molecular weight ~3647 Da for the DAC form. trial
Stacks
- Solo DAC: Common choice when the goal is fewer injections and steady IGF-1 without multi-daily GHRP logistics. forum
- DAC + Ipamorelin: Weekly (or 2×/week) DAC plus daily or bedtime Ipamorelin (~100–300 mcg Ipa per pulse in usual GHRP ranges) — hybrid of long GHRH exposure + short ghrelin-path pulse. Pulse purists often call this philosophically messy; convenience users like it. forum
- DAC + GHRP-2 / GHRP-6 / Hexarelin: Older stack talk; more hunger (GHRP-6), cortisol/prolactin, or desensitization lore than Ipamorelin in forum culture. forum
- Switch not stack (vs no-DAC): Many drop DAC for Mod GRF + GHRP rather than run both GHRH forms together. forum
- Avoid double-GHRH overload: DAC + no-DAC + sermorelin together is generally seen as redundant and side-amplifying without clear upside. forum
- + BPC-157 / TB-500: “Recover harder” lifestyle stacks — highly confounded; not a formal GH endpoint protocol. forum
- Cut phase: Discussed alongside deficits and cardio as a recomp assist, not a standalone fat burner. forum
- vs MK-677 (ibutamoren): Oral continuous secretagogue comparison; MK more appetite/water/glucose talk for many; DAC is inject weekly vs oral daily. forum
- vs Sermorelin: Short classic GHRH fragment / clinic branding vs long-acting DAC. forum
- vs exogenous HGH: Sometimes framed as cheaper “stimulate own GH” bridge; outcomes and side profile still differ from pharmacologic rGH. forum
- TRT / men’s clinic adjacency: Occasionally layered in wellness-forum protocols with testosterone replacement — confounded. forum
- vs Tesamorelin: Stronger clinical visceral-adipose framing (Egrifta history) vs research-chem DAC convenience culture — not 1:1 dose charts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Flushing: Transient facial flush or warmth soon after injection in a subset. forum
- Water retention / edema: Mild peripheral edema, facial fullness, ring tightness, scale noise from fluid — more discussed with sustained multi-day GH/IGF-1 than with single short pulses. forum
- Lethargy / daytime sleepiness: Subset reports fatigue or sleepiness during elevated windows. forum
- Joint stiffness / muscle aches: GH-elevation pattern talk; stacks and training confound. forum
- Paresthesias / carpal-tunnel-like numbness: Hand/finger tingling or numbness framed as fluid pressure — more on aggressive or long GH-axis exposure. forum
- Glucose / insulin: GH can oppose insulin action; community flags fasting glucose / metabolic risk factors on longer runs. forum
- Appetite: Mixed; some note increased appetite in GH-axis context; less extreme than GHRP-6-driven hunger. forum
- Insomnia vs better sleep: Split reports — deeper sleep for some, restless sleep for others. anecdote
- Sustained elevation unknowns: Multi-day elevated trough GH/IGF-1 raises theoretical long-term questions (metabolic, proliferative pathway talk) without multi-year healthy-athlete RCTs. forum
- Cancer / mitogenic caution: Standard GH/IGF-1 pathway warning for active or high-risk malignancy history — not a DAC-specific carcinogenicity trial endpoint. forum
- Harder to reverse quickly: Multi-day half-life means sides do not clear as fast as after a single no-DAC pulse — practical titration caution. forum
- Pregnancy / unknowns: No adequate safety database for pregnancy, breastfeeding, or multi-year unmonitored wellness use. forum
- Injection site (trial + logs): Pain, redness, swelling, mild erythema, itch, or induration — most common documented adverse events in healthy-adult studies and community use. trial
- Headache: Appears in trial AE lists and community logs. trial
- Diarrhea / GI: Listed among minor trial-period side effects in secondary summaries of early studies. trial
- Hypertension note: Occasional mention in side-effect compilations of early clinical experience — not a modern large-safety database. trial
- Development history / trial death: ConjuChem Phase II lipodystrophy / related program dosing halted ~July 2006 after a participant death (Argentina site in contemporary reports; secondary sources describe acute MI ~hours after a dose). Attending physician favored asymptomatic CAD with plaque rupture unrelated to drug; program discontinued as precaution. Not a full consumer risk table, but a durable history flag. trial
- Not FDA-approved for bodycomp: No approved indication for muscle, fat loss, sleep, or anti-aging; remains research / gray-market and discontinued clinical development context. trial
- Long-term data gap: Controlled multi-year athletic and safety outcome data for weekly DAC self-experimentation essentially do not exist beyond early short healthy-adult PK/PD work. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.